Table 3.
Treatment effectiveness for the 12 months after the index switch, using the claims-based algorithm
| Algorithm criterion | Patients achieving the criterion, n (%)
|
Pa | ||
|---|---|---|---|---|
| All patients (N=6,945) | TNFi cyclers (n=5,020) | Non-TNFi switchers (n=1,925) | ||
| Satisfied all six algorithm criteria | 1,724 (24.8) | 1,205 (24.0) | 519 (27.0) | 0.011 |
| Adherent | 2,809 (40.4) | 2,006 (40.0) | 803 (41.7) | 0.182 |
| No increase in the targeted | 6,257 (90.1) | 4,429 (88.2) | 1,828 (95.0) | <0.001 |
| DMARD dose | ||||
| No new conventional synthetic | 5,901 (85.0) | 4,253 (84.7) | 1,648 (85.6) | 0.353 |
| DMARD | ||||
| No targeted DMARD switch | 4,635 (66.7) | 3,282 (65.4) | 1,353 (70.3) | <0.001 |
| No new/increased glucocorticoid | 5,935 (85.5) | 4,304 (85.7) | 1,631 (84.7) | 0.285 |
| Less than two intra-articular injections | 6,294 (90.6) | 4,549 (90.6) | 1,745 (90.6) | 0.968 |
Note:
a
Pairwise comparison of TNFi cyclers and non-TNFi switchers by chi-square test.
Abbreviations: DMARD, disease-modifying antirheumatic drug; TNFi, tumor necrosis factor inhibitor.